Novo Nordisk Research Early Development 2024 Strategy

Novo Nordisk's research and early development presentation outlines strategic aspirations in diabetes, obesity, and rare diseases through 2025. The company aims to strengthen its diabetes market leadership, achieve over 25 billion DKK in obesity sales, and advance its rare disease and cardiovascular pipelines while maintaining operational efficiency and sustainable growth.